A drug that frees the immune system to attack a devastating form of lung cancer has been shown to double the life expectancy of genetically targeted patients . Nivolumab is one of new generation of immunotherapy drugs that release cancer-applied brakes on the immune system called “checkpoints”.

Click here to read original article